Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for WuXi Biologics (Cayman)'s EV-to-OCF or its related term are showing as below:
FRA:1FW2'
s EV-to-OCF Range Over the Past 10 Years
Min: 8.1 Med: 82.33 Max: 592.05
Current: 26.5
During the past 12 years, the highest EV-to-OCF of WuXi Biologics (Cayman) was 592.05. The lowest was 8.10. And the median was 82.33.
FRA:1FW2's EV-to-OCF is ranked worse than 91.02% of 1403
companies
in the Biotechnology industry
Industry Median: -3.36
vs FRA:1FW2: 26.50
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
WuXi Biologics (Cayman)'s PE Ratio (TTM) for today is calculated as:
WuXi Biologics (Cayman)'s share price for today is €5.84.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi Biologics (Cayman)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.145.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1FW2 vs VRTX, REGN, MRNA: EV-to-OCF Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s EV-to-OCF distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s EV-to-OCF falls into.
WuXi Biologics (Cayman)'s current Enterprise Value is €22,081 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi Biologics (Cayman)'s Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was € Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is WuXi Biologics (Cayman) (FRA:1FW2) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be overvalued.
The current stock price of €5.84 is trading 34.3% above its estimated GF Value™ of €4.35.
GuruFocus considers WuXi Biologics (Cayman) to be Significantly Overvalued.
Key valuation signals for FRA:1FW2:
EV-to-OCF:
GF Value™: €4.35 vs. price of €5.84 (34.3% above fair value)
No single metric tells the full story. See the FRA:1FW2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
92GF Score
Get the complete analysis for FRA:1FW2
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1FW2 has been successfully added to your 
